FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average but	rden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed gurgoset to Cookies 10(a) of the Cookies Fusbance Act of 1004

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOHLIN GAREN G (Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE					3. D 05/	Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC [COLL] 3. Date of Earliest Transaction (Month/Day/Year) 05/20/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)							NC (5. Relationship of Reporting F Check all applicable) X Director Officer (give title below) 6. Individual or Joint/Group Fi ine)				10% Ov Other (s below)	wner specify
(Street) STOUGHTON MA 02072													X Form filed by One Reporting Person Form filed by More than One Reporting Person					- 1	
(City)	(St	ate) ((Zip)																
		Tab	le I - Non	-Deriv	ative	Sec	curitie	s Ac	quired,	Dis	posed o	of, or Be	enefici	ally	Owned	l .			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		Code (Instr. 5)			red (A) oi str. 3, 4 a	and Securities Beneficia		es For ally (D) Following (I) (n: Direct r Indirect sstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)			Transact (Instr. 3	ion(s)			(111501.4)	
Common Stock 05/20/)/2020	/2020 A 4,047 ⁽¹⁾ A		. \$	0	11,007			D							
		T	able II - I (uired, C s, optior	•		,		•	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transactio Code (Insti 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		expiration vate	Title	Amoun or Number of Shares	r					
Stock Option (Right to	\$22.05	05/20/2020			A		8,095		(2)	0	5/20/2030	Common Stock	8,095		\$0	8,095	;	D	

Explanation of Responses:

1. Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

2. The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer.

Remarks:

/s/ Paul Brannelly as Attorney-In-Fact For Garen G. Bohlin 05/22/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.